New post-market registry data shows that the first two FDA-approved cardiac rhythm management devices without transvenous leads are performing about as well as could be hoped in the "real world."
At the Heart Rhythm Society Scientific Sessions in Chicago on May 11, Mikhael El-Chami of Emory University in Atlanta reported acute results from 795 patients in the post-approval registry of...